Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: Preparation, characterization and in vitro studies

Journal of Microencapsulation

Volumn 27, Issue 8, 2010, Pages 726-734

  Liu, Dongfei ^a   Ge, Yifan ^a   Tang, Yue ^b   Yuan, Yubing ^a   Zhang, Qing ^a   Li, Rui ^a   Xu, Qunwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Diclofenac sodium; Formulation optimization; in vitro cutaneous permeation; in vitro release; Solid lipid nanoparticles

Indexed keywords

COSURFACTANT; DICLOFENAC; EMULSIFYING AGENT; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE;

ARTICLE; DRUG ANALYSIS; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MICROENCAPSULATION; SKIN PERMEABILITY; TRANSDERMAL DRUG ADMINISTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICLOFENAC; DIFFUSION CHAMBERS, CULTURE; DRUG DELIVERY SYSTEMS; EMULSIONS; EXCIPIENTS; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS; RATS; SKIN ABSORPTION; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS;

EID: 78049452286     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2010.513456     Document Type: Article

References (32)

1. Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, OBrien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP, EDGE Study Group. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: Results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) Trial. J Rheumatol, 2007;34:408-20.
2. Baydoun L, Muller-Goymann CC. Influence of n-octenylsuccinate starch on in vitro permeation of sodium diclofenac across excised porcine cornea in comparison to Voltaren ophtha. Eur J Pharm Biopharm, 2003;56:73-9.
3. Boonsongrit Y, Mitrevej A, Mueller BW. Chitosan drug binding by ionic interaction. Eur J Pharm Biopharm, 2006;62:267-74.
4. Castro GA, Coelho ALLR, Oliveira CA, Mahecha GAB, Orefice RL, Ferreira LAM. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm, 2009;381:77-83.
5. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur JPharm Biopharm, 1996;42:110-5.
6. Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Control Release, 2010;141:277-99.
7. Cortesi R, Esposjto E, Luca G, Nastruzzi C. Production of lipospheres as carriers for bioactive compounds. Biomaterials, 2002;23:2283-94.
8. Cui FD, Shi K, Zhang LQ, Tao AJ, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J Control Release, 2006;114:242-50.
9. Dickinson E. Hydrocolloids as emulsifiers and emulsion stabilizers. Food Hydrocolloid, 2009;23:1473-82.
10. Djekic L, Primorac M. The influence of cosurfactants and oils on the formation of pharmaceutical microemulsions based on PEG-8 caprylic/capric glycerides. Int J Pharm, 2008;352:231-9.
11. Godin B, Touitou E. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev, 2007;59:1152-61.
12. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Control Release, 1999;57:171-85.
13. Heiati H, Phillips NC, Tawashi R. Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res, 1996;13:1406-10.
14. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm, 2006;314:83-9.
15. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release, 2007;119:197-206.
16. Jain SK, Chourasia MK, Masuriha R, Soni V, Jain A, Jain NK, Gupta Y. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv, 2005;12:207-15.
17. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm, 2008;346:124-32.
18. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol, 2010;50:50-61.
19. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm, 2006;312:179-86.
20. Liu J, Gong T, Wang CG, Zhong ZR, Zhang ZR. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization. Int J Pharm, 2007;340:153-62.
21. Magenheim B, Levy MY, Benita S. A new in vitro technique for the evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm, 1993;94:115-23.
22. Muller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm, 2004;58:343-56.
23. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161-77.
24. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 2002;54:131-55.
25. Myers D, 1999. Surfaces, interfaces and colloids: Principles and applications. 2nd ed. New York: Wiley-VCH. pp 253-94.
26. Nokhodchi A, Nazemiyeh H, Ghafourian T, Hassan-Zadeh D, Valizadeh H, Bahary LAS. The effect of glycyrrhizin on the release rate and skin penetration of diclofenac sodium from topical formulations. Il Farmaco, 2003;57:883-8.
27. Nokhodchi A, Sharabiani K, Rashidi MR, Ghafourian T. The effect of terpene concentrations on the skin penetration of diclofenac sodium. Int J Pharm, 2007;335:97-105.
28. Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol, 2007;7:3596-601.
29. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, Levy RJ. Formulation and characterisation of biodegradable nanoparticles for intravascular local drug delivery. J Control Release, 1997;43:197-212.
30. Todd PA, Sorkin EM. Diclofenac sodium, a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 1988;35:244-85.
31. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm, 2003;257:153-60.
32. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in ice of intravenously injected camptothecin solid lipid nanoparticles nd targeting effect on brain. J Control Release,1999;59:299-307.